Update on Interventions to Protect High-Risk Patients From Invasive Fungal Infections

Learn to risk stratify patients, select optimal prophylactic therapy, and manage breakthrough fungal infections with this downloadable slideset.
Thomas F. Patterson, MD, FACP, FIDSA
Program Director
George R. Thompson III, MD, FIDSA
Format: Microsoft PowerPoint (.ppt)
File Size: 1.54 MB
Released: April 24, 2019

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Astellas

Related Content

CME-certified video from CCO on emerging therapies with novel MoAs for invasive fungal infections such as candidiasis, aspergillosis, and mucormycosis

Thomas F. Patterson, MD, FACP, FIDSA
Program Director
James Lewis, PharmD, FIDSA George R. Thompson III, MD, FIDSA
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 24, 2019 Expiration: April 23, 2020

CME/CE-certified video with expert discussion on the treatment of invasive fungal infections such as candidiasis, aspergillosis, and mucormycosis

Thomas F. Patterson, MD, FACP, FIDSA
Program Director
James Lewis, PharmD, FIDSA George R. Thompson III, MD, FIDSA
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 24, 2019 Expiration: April 23, 2020

CME/CE-certified video with expert discussion on prophylaxis for invasive fungal infections such as candidiasis, aspergillosis, and mucormycosis

Thomas F. Patterson, MD, FACP, FIDSA
Program Director
James Lewis, PharmD, FIDSA George R. Thompson III, MD, FIDSA
Physicians: maximum of 1.0 AMA PRA Category 1 Credit Registered Nurses: 1.0 Nursing contact hour Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 24, 2019 Expiration: April 23, 2020

Downloadable slides with guidance on treatment of invasive fungal infections such as candidiasis, aspergillosis, and mucormycosis in high-risk patients

Thomas F. Patterson, MD, FACP, FIDSA
Program Director
James Lewis, PharmD, FIDSA
Released: April 24, 2019

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?